Medical Treatment of Hepatorenal Syndrome - AASLD

More documents

Recommendations

Info

Adverse EventsTerlipressinN=56PlaceboN=55Adverse Events 93 % 89 %Related 32 % 22 %Serious AEs 66 % 66 %Related 9 % 2 %Deaths 48 % 49 %Related 0 % 0 %Withdrawals due to AE 5 % 4 %Related 5 % 0 %
Midodrine plus Octreotideplus albumin in HRS type 1Test 0 10 20daysCreat. 5.0 4.6 3.3RPF 61 82 181Aldo. 1349 636 379PRA 17 8 5Hepatology 29:1690;1999
Page 1 and 2: Thomas D. Boyer, MDHepatorenal Synd
Page 3 and 4: Conflicts of interest• Member adv
Page 5 and 6: Pathogenesis of Ascites in Cirrhosi
Page 7 and 8: 7060504030252015105Neurohumoral Sys
Page 9 and 10: Type and Frequency of Injury inAcut
Page 11: Workup of Renal Dysfunction in Pati
Page 14 and 15: Hepatorenal syndromeAdditional Crit
Page 16 and 17: Type 1 HRS Is Associated WithVery P
Page 18 and 19: Who Develops HRS?•Cirrhotic patie
Page 20 and 21: Prevention of HRS
Page 22 and 23: Antibiotic Prophylaxis in VaricealB
Page 24 and 25: Prostaglandin Inhibition andEffects
Page 26 and 27: Treatment of HRS General• Stop al
Page 28 and 29: Site of Action of CurrentTherapies
Page 30 and 31: TIPS and HRSGut 47:166; 2000
Page 32 and 33: Treatment of HRS:Pharmacologic Ther
Page 34 and 35: Background (II)• Synthetic 12-ami
Page 36 and 37: Reversal of HRS40HRS Reversal (%)30
Page 38 and 39: Survival DistributionFunction1.00.9
Page 42 and 43: Impact of OLTx on RenalGlomerular f
Page 44 and 45: HRS conclusions continued• Exclus

Medical Treatment of Hepatorenal Syndrome - AASLD

Create successful ePaper yourself

Delete template?

Save as template?